Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The companies will work to seek the regulatory approval for Foundation Medicine assays which detect mutations including BRAFV600E to identify patients for potential treatment with Pierre’s BRAF/MEK inhibitor, BRAFTOVI (encorafenib) and MEKTOVI (binimetinib), in the EU.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Foundation Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 15, 2023
Details:
Braftovi (encorafenib) + Mektovi (binimetinib) is approved for the treatment of adult patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC), who are either treatment naïve or have received prior therapy.
Lead Product(s): Encorafenib,Binimetinib
Therapeutic Area: Oncology Product Name: Braftovi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
Under the terms of the agreement, Pierre Fabre gains U.S. and remaining global commercial markets for tab-cel (tabelecleucel), an allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy.
Lead Product(s): Tabelecleucel
Therapeutic Area: Infections and Infectious Diseases Product Name: Tab-cel
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Recipient: Atara Biotherapeutics
Deal Size: $640.0 million Upfront Cash: $30.0 million
Deal Type: Partnership November 01, 2023
Details:
STX-721, Scorpion's highly differentiated, orally bioavailable, irreversible highly selective tyrosine kinase inhibitor targeting EGFR and ERBB2 (HER2) Exon 20 insertion mutations, well-known, clinically validated oncogenic drivers in non-small cell lung cancer.
Lead Product(s): STX-721
Therapeutic Area: Oncology Product Name: STX-721
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Scorpion Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
Under the terms of the collaboration, Vernalis will use its expertise to enable drug discovery against an undisclosed portfolio of multiple oncology targets and use fragment and structure-based methods to identify small molecules that modulate their activity.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Vernalis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 25, 2023
Details:
The acquisition allows Pierre to add VERT-002 to its oncology discovery pipeline. VERT-002 is a monoclonal antibody, acting as a degrader of c-MET. This target is a known disease driver in patients suffering from NSCLC with mutations or amplification of MET.
Lead Product(s): VERT-002
Therapeutic Area: Oncology Product Name: VERT-002
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Vertical bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 12, 2023
Details:
Under the agreement, Terran obtains exclusive global development and commercialization rights for idazoxan hydrochloride, a selective alpha 2 receptor antagonist and a late-stage clinical therapeutic for the treatment of schizophrenia.
Lead Product(s): Idazoxan
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Terran Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 02, 2023
Details:
Under the agreement, Scorpion will lead development of STX-721 and Pierre Fabre will lead development of STX-241. Scorpion will retain commercialization rights to STX-721 and STX-241 in US, Canada and Japan, and Pierre Fabre will retain commercialization in other territories.
Lead Product(s): STX-721
Therapeutic Area: Oncology Product Name: STX-721
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Scorpion Therapeutics
Deal Size: $618.0 million Upfront Cash: $65.0 million
Deal Type: Collaboration April 04, 2023
Details:
Ebvalloâ„¢ (tabelecleucel) is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in an HLA-restricted manner.
Lead Product(s): Tabelecleucel
Therapeutic Area: Infections and Infectious Diseases Product Name: Ebvallo
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Atara Biotherapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
The agreement will support a clinical proof-of-concept trial evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the anti-EGFR antibody cetuximab for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Lead Product(s): ERAS-007,Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: ERAS-007
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Erasca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 30, 2022